In vivo LNP-CRISPR Approaches for the Treatment of Hemophilia-Reference-Cited by-同舟云学术

In vivo LNP-CRISPR Approaches for the Treatment of Hemophilia

Published:2024-03-28 Issue:3 Volume:28 Page:239-248
ISSN:1177-1062
Container-title:Molecular Diagnosis & Therapy
language:en
Short-container-title:Mol Diagn Ther

Author:

Lee Jeong Hyeon,Han Jeong Pil^ORCID

Funder

Seoul National University

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40291-024-00705-1.pdf

Reference100 articles.

1. Garagiola I, et al. X Chromosome inactivation: a modifier of factor VIII and IX plasma levels and bleeding phenotype in Haemophilia carriers. Eur J Hum Genet. 2021;29(2):241–9.

2. Castaman G, et al. Mild and moderate hemophilia a: neglected conditions, still with unmet needs. MDPI; 2023. p. 1368.

3. Iorio A, et al. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med. 2019;171(8):540–6.

4. Thorat T, Neumann PJ, Chambers JD. Hemophilia burden of disease: a systematic review of the cost-utility literature for hemophilia. J Manag Care Spec Pharm. 2018;24(7):632–42.

5. Ndoumba-Mintya A, et al. Optimizing haemophilia care in resource-limited countries: current challenges and future prospects. J Blood Med. 2023;14:141–6.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug‐induced liver injury related to gene therapy: A new challenge to be managed;Liver International;2024-09-09

2. Engineering strategies to safely drive CAR T-cells into the future;Frontiers in Immunology;2024-06-19